Sripathi M Sureban, M Pharm

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/227975/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Identification of a Novel Putative Gastrointestinal Stem Cell and Adenoma Stem Cell Marker, Doublecortin and CaM Kinase-Like-1, Following Radiation Injury and in Adenomatous Polyposis Coli/Multiple Intestinal Neoplasia Mice. Stem Cells, 2008, 26, 630-637.	1.4	251
2	DCAMKL-1 Regulates Epithelial–Mesenchymal Transition in Human Pancreatic Cells through a <i>miR-200a</i> –Dependent Mechanism. Cancer Research, 2011, 71, 2328-2338.	0.4	192
3	Knockdown of RNA Binding Protein Musashi-1 Leads to Tumor Regression In Vivo. Gastroenterology, 2008, 134, 1448-1458.e2.	0.6	163
4	Doublecortin and CaM Kinase-like-1 and Leucine-Rich-Repeat-Containing G-Protein-Coupled Receptor Mark Quiescent and Cycling Intestinal Stem Cells, Respectively. Stem Cells, 2009, 27, 2571-2579.	1.4	153
5	Diphenyl Difluoroketone: A Curcumin Derivative with Potent <i>In vivo</i> Anticancer Activity. Cancer Research, 2008, 68, 1962-1969.	0.4	147
6	Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism. Journal of Nanobiotechnology, 2011, 9, 40.	4.2	138
7	DCLK1 Regulates Pluripotency and Angiogenic Factors via microRNA-Dependent Mechanisms in Pancreatic Cancer. PLoS ONE, 2013, 8, e73940.	1.1	132
8	Selective Blockade of DCAMKL-1 Results in Tumor Growth Arrest by a Let-7a MicroRNA-Dependent Mechanism. Gastroenterology, 2009, 137, 649-659.e2.	0.6	109
9	XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism. Cancer Letters, 2014, 351, 151-161.	3.2	107
10	Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1. Molecular Cancer, 2014, 13, 103.	7.9	102
11	Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells. Molecular Cancer, 2017, 16, 30.	7.9	91
12	DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma. Oncotarget, 2015, 6, 2193-2205.	0.8	85
13	Identification of a novel putative pancreatic stem/progenitor cell marker DCAMKL-1 in normal mouse pancreas. American Journal of Physiology - Renal Physiology, 2010, 299, G303-G310.	1.6	79
14	Hepatitis C Virus-Induced Cancer Stem Cell-Like Signatures in Cell Culture and Murine Tumor Xenografts. Journal of Virology, 2011, 85, 12292-12303.	1.5	74
15	Brief Report: Dclk1 Deletion in Tuft Cells Results in Impaired Epithelial Repair After Radiation Injury. Stem Cells, 2014, 32, 822-827.	1.4	73
16	Dclk1 facilitates intestinal tumor growth via enhancing pluripotency and epithelial mesenchymal transition. Oncotarget, 2014, 5, 9269-9280.	0.8	71
17	Functional Antagonism Between RNA Binding Proteins HuR and CUGBP2 Determines the Fate of COX-2 mRNA Translation. Gastroenterology, 2007, 132, 1055-1065.	0.6	68
18	Identification of the putative intestinal stem cell marker doublecortin and CaM kinaseâ€likeâ€1 in Barrett's esophagus and esophageal adenocarcinoma. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 773-780.	1.4	63

#	Article	IF	CITATIONS
19	Ablation of Doublecortin-Like Kinase 1 in the Colonic Epithelium Exacerbates Dextran Sulfate Sodium-Induced Colitis. PLoS ONE, 2015, 10, e0134212.	1.1	58
20	Reg IV Regulates Normal Intestinal and Colorectal Cancer Cell Susceptibility to Radiation-Induced Apoptosis. Gastroenterology, 2010, 138, 616-626.e2.	0.6	52
21	Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism. Oncotarget, 2015, 6, 37200-37215.	0.8	47
22	Doublecortin-Like Kinase 1 Is Elevated Serologically in Pancreatic Ductal Adenocarcinoma and Widely Expressed on Circulating Tumor Cells. PLoS ONE, 2015, 10, e0118933.	1.1	42
23	Dclk1+ small intestinal epithelial tuft cells display the hallmarks of quiescence and self-renewal. Oncotarget, 2015, 6, 30876-30886.	0.8	40
24	Intestinal tuft cells regulate the ATM mediated DNA Damage response via Dclk1 dependent mechanism for crypt restitution following radiation injury. Scientific Reports, 2016, 6, 37667.	1.6	37
25	DCLK1 Monoclonal Antibody-Based CAR-T Cells as a Novel Treatment Strategy against Human Colorectal Cancers. Cancers, 2020, 12, 54.	1.7	37
26	DCLK1 Is Detectable in Plasma of Patients with Barrett's Esophagus and Esophageal Adenocarcinoma. Digestive Diseases and Sciences, 2015, 60, 509-513.	1.1	33
27	Inhibition of Notch signaling reduces the number of surviving Dclk1 ⁺ reserve crypt epithelial stem cells following radiation injury. American Journal of Physiology - Renal Physiology, 2014, 306, G404-G411.	1.6	32
28	Fluvastatin Interferes with Hepatitis C Virus Replication via Microtubule Bundling and a Doublecortin-like Kinase-Mediated Mechanism. PLoS ONE, 2013, 8, e80304.	1.1	31
29	(Z)-3,5,4′-Trimethoxystilbene Limits Hepatitis C and Cancer Pathophysiology by Blocking Microtubule Dynamics and Cell-Cycle Progression. Cancer Research, 2016, 76, 4887-4896.	0.4	28
30	Dietary Pectin Increases Intestinal Crypt Stem Cell Survival following Radiation Injury. PLoS ONE, 2015, 10, e0135561.	1.1	27
31	Inflammatory and oncogenic roles of a tumor stem cell marker doublecortin-like kinase (DCLK1) in virus-induced chronic liver diseases. Oncotarget, 2015, 6, 20327-20344.	0.8	27
32	Loss of p21 ^{Waf1/Cip1/Sdi1} enhances intestinal stem cell survival following radiation injury. American Journal of Physiology - Renal Physiology, 2009, 296, G245-G254.	1.6	24
33	Regulation of miRNAs by Agents Targeting the Tumor Stem Cell Markers DCLK1, MSI1, LGR5, and BMI1. Current Pharmacology Reports, 2015, 1, 217-222.	1.5	12
34	Therapeutic Effects of Phyllanthus Species: Induction of TNF-α-mediated Apoptosis in HepG2 Hepatocellular Carcinoma Cells. American Journal of Pharmacology and Toxicology, 2006, 1, 65-71.	0.7	9
35	Could Nutraceutical Approaches Possibly Attenuate the Cytokine Storm in COVID-19 Patients?. Frontiers in Cellular and Infection Microbiology, 2021, 11, 667733.	1.8	5
36	Knockdown of Musashi-1 Results in Tumor Growth Arrest Through Inhibition of c-MYC, Notch-1 and EMT by Let-7a, Mir-144 and Mir-200a MicroRNAs Dependent Mechanisms Respectively. Gastroenterology, 2011, 140, S-48.	0.6	3

#	Article	IF	CITATIONS
37	Cyclooxygenase-2 Gene Expression. , 2006, , 197-218.		2
38	Comparative Evaluation of Novel Putative Stem Cell Markers and Tumor Suppressor MicroRNAs in Barrett's Esophagus. Gastroenterology, 2011, 140, S-224.	0.6	2
39	Mo1304 Dietary Omega-3 Polyunsaturated Fatty Acids Increase Intestinal Crypt Stem Cell Survival Following Radiation Injury. Gastroenterology, 2016, 150, S692.	0.6	2
40	Cancer Stem Cells and Pluripotency. Pancreatic Disorders & Therapy, 2012, 02, .	0.3	2
41	Journal of Basic and Clinical Pharmacy signs collaboration agreement with Medknow Publications-Wolters Kluwer Health. Journal of Basic and Clinical Pharmacy, 2012, 3, 329.	9.3	2
42	S1942 Selective Blockade of DCAMKL-1 Results in Tumor Growth Arrest By a Let-7a MicroRNA Dependent Mechanism. Gastroenterology, 2009, 136, A-298.	0.6	1
43	Sa1824 Dietary Pectin Increases Intestinal Crypt Stem Cell Survival Following Radiation Injury. Gastroenterology, 2012, 142, S-334.	0.6	1
44	Epigenetic Variants and Biomarkers for Colon Cancer. American Journal of Pathology, 2012, 180, 2205-2207.	1.9	1
45	Epigenetic Variations of Stem Cell Markers in Cancer. , 2013, , 115-128.		1
46	Abstract 4220: Silencing DCLK1 prevents breast cancer cell self-renewal, epithelial mesenchymal transition, circulating tumor cells and metastasis. , 2015, , .		1
47	Abstract 2493: Knocking down the expression of DCLK1 reduces mammary tumor formation, tumor cell self-renewal and metastasis: DCLK1 a novel therapeutic target in breast cancer. Cancer Research, 2016, 76, 2493-2493.	0.4	1
48	Crystal Structure of 3a-Hydroxy-3,5a,9-trimethyl 1,3,3a,4,5,5a,6,7,8,9b decahydro-2H naphtha[1,2c]-imidazole-2-one Monohydrate from the Plant Sphaeranthus indicus. Analytical Sciences: X-ray Structure Analysis Online, 2005, 21, X99-X100.	0.1	0
49	614 RNA Binding Protein RBM3: A Novel Protooncogene Required for Tumor Cells to Overcome G2/M Arrest and Mitotic Catastrophe. Gastroenterology, 2008, 134, A-86.	0.6	Ο
50	615 Knockdown of Musashi-1 Results in p21Waf-1 Induction During G2/M Arrest and Mitotic Catastrophe Via Inhibition of Notch Signaling. Gastroenterology, 2008, 134, A-86.	0.6	0
51	657 Distinguishing Quiescent Stem Cells from Cycling Progenitor Cells in Intestinal Crypts with the Recently Identified Novel Markers Dcamkl-1 and Lgr5. Gastroenterology, 2008, 134, A-96.	0.6	Ο
52	S1872 A Novel In Vitro Detection Method to Identify Dietary Chemopreventive Agents Utilizing the NF-κB Pathway. Gastroenterology, 2008, 134, A-286.	0.6	0
53	S1645 Epidermal Growth Factor Induces Expression of Protooncogene RBM3 Through p38 and erK Resulting in Increased COX-2 Expression. Gastroenterology, 2008, 134, A-241.	0.6	0
54	60 Identification of a Novel Pancreatic Stem Cell Marker DCAMKL-1 in Mouse Pancreas and in Pancreatic Cancer. Gastroenterology, 2009, 136, A-10.	0.6	0

#	Article	IF	CITATIONS
55	S1685 Inhibition of Notch Signaling Decreases Intestinal Stem Cell Survival Following Radiation Injury. Gastroenterology, 2010, 138, S-253.	0.6	0
56	267 Knockdown of DCAMKL-1 Results in Tumor Growth Arrest Through Inhibition of Notch1 by a Mir-144 MicroRNA Dependent Mechanism. Gastroenterology, 2010, 138, S-49.	0.6	0
57	411 Role of Intestinal Stem Cell Marker DCAMKL-1 in Pancreatic Cancer. Gastroenterology, 2010, 138, S-61.	0.6	Ο
58	DCAMKL-1 Expression in Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterology, 2011, 140, S-308.	0.6	0
59	Nanoparticle-Based Delivery of DCAMKL-1 SiRNA and DAPT Increases MicroRNA-144 and Inhibits Colorectal Cancer Tumor Growth via a Notch-1 Dependent Mechanism. Gastroenterology, 2011, 140, S-122.	0.6	Ο
60	Role of Doublecortin and CAM Kinase-Like-1 (DCAMKL-1) in Hepatitis C Virus-Induced Hepatocarcinogenesis. Gastroenterology, 2011, 140, S-972.	0.6	0
61	Knockdown of DCAMKL-1 Results in Liver Cancer Tumor Growth Arrest Through Inhibition of c-MYC via Let-7a MicroRNA; Inhibits EMT via Mir-200a MicroRNA Dependent Mechanisms. Gastroenterology, 2011, 140, S-890.	0.6	Ο
62	Mo1881 The Expression of Putative Pancreatic Stem Cell Marker DCAMKL-1 is Elevated in Early Stage Pancreatic Adenocarcinoma Patients. Gastroenterology, 2012, 142, S-1086.	0.6	0
63	Su1869 DCAMKL-1 Regulates Pluripotency Factors Oct4, SOX2 and KLF4 via miR-145 MicroRNA Dependent Mechanism. Gastroenterology, 2012, 142, S-523.	0.6	0
64	208 DCAMKL-1 Regulates BMI1 Expression in Colorectal and Pancreatic Cancer Cells. Gastroenterology, 2012, 142, S-51.	0.6	0
65	Sa1800 Systemic Delivery of Nanoparticle-Encapsulated SiRNA Targeting DCAMKL-1 Results in Reduced Intestinal Polyposis in APCMIN/+ Mice. Gastroenterology, 2012, 142, S-329.	0.6	Ο
66	Su1842 Role of DCAMKL-1+ Stem Cells in Epithelial-Mesenchymal Transition and Intestinal Neoplasia. Gastroenterology, 2012, 142, S-517.	0.6	0
67	Tu1735 DCLK1 Deletion in Mouse Small Intestinal Tuft Cells Results in Impaired Epithelial Restoration Following Radiation Injury. Gastroenterology, 2013, 144, S-833-S-834.	0.6	0
68	Mo1805 Ablation of DCLK1 in Intestinal Epithelium Exacerbates Colonic Epithelial Barrier Damage in Response to DSS Treatment. Gastroenterology, 2013, 144, S-668.	0.6	0
69	Tu1903 Expression of a Novel Stem Cell Marker Doublecortin-Like Kinase 1 (DCLK1) in Human Colorectal Polyps and Adenocarcinomas. Gastroenterology, 2013, 144, S-876-S-877.	0.6	Ο
70	404 Functional Significance of DCLK1 in the Regulation of Molecular Signaling Is Critical for Intestinal Epithelial Cell Functioning/Survival Following 24h Radiation Injury. Gastroenterology, 2013, 144, S-78-S-79.	0.6	0
71	241 Small Molecule Inhibitors Xmd8-92 and Pv1019 Inhibit Pancreatic Tumor Xenograft Growth via a DCLK1 Dependent Mechanism. Gastroenterology, 2013, 144, S-53.	0.6	0
72	Tu1693 DCLK1 Enhances Epithelial Pluripotency and Oncogenic Signaling During Intestinal Tumor Progression. Gastroenterology, 2014, 146, S-820.	0.6	0

#	Article	IF	CITATIONS
73	Su1862 RNA Binding Protein Musashi-1 Regulates Tumorigenesis and Angiogenesis via MicroRNA-Dependent Mechanism. Gastroenterology, 2014, 146, S-488.	0.6	0
74	Su1997 Ablation of Mesenchymal DCLK1 by the Foxl1-Cre Promoter Results in Increased Epithelial Tuft Cells. Gastroenterology, 2014, 146, S-518.	0.6	0
75	Tu1216 DCLK1 Regulates Intestinal Epithelial Self-Renewal, Survival Signaling Pathways and DNA Repair Machinery in Response to Genotoxic Injury. Gastroenterology, 2014, 146, S-786.	0.6	Ο
76	Mo1929 Small-Molecule Parkinson's Disease Kinase Inhibitor LRRK2-in-1 Demonstrates Potent Anti-Cancer Activity Through Inhibition of DCLK1. Gastroenterology, 2014, 146, S-694.	0.6	0
77	Su2006 The DCLK1 Tumor Stem Cell Marker Is a Central Regulatory Component of the Epithelial-Mesenchymal Transition Program in Colorectal Cancer. Gastroenterology, 2015, 148, S-573.	0.6	Ο
78	Su2005 DCLK1 Promotes Pancreatic Cancer Cell Clonogenicity and Invasiveness. Gastroenterology, 2015, 148, S-572-S-573.	0.6	0
79	130 DCLK1 Regulates COX-2 via miR-144 microRNA-Dependent Mechanism. Gastroenterology, 2015, 148, S-34.	0.6	0
80	674 dclk1+ Tuft Cells Display Quiescent Stem Cell-Like Properties in the Small Intestine. Gastroenterology, 2015, 148, S-130.	0.6	0
81	Sa1426 Dclk1+ Tuft Cells Regulate IEC Self-Renewal and Survival in Response to Injury via a Prostanoids/Prostaglandin Dependent Mechanism. Gastroenterology, 2016, 150, S312.	0.6	0
82	197 Tempol, Telmisartan, and Yk-4-250 Act As Radiation Mitigators, Prevent GI Acute Radiation Syndrome, and Promote Overall Survival Following Radiation Injury. Gastroenterology, 2016, 150, S51-S52.	0.6	0
83	456 – Dclk1 Monoclonal Antibody-Based Car-T Cells As Novel Treatment Strategy Against Human Colorectal Cancers. Gastroenterology, 2019, 156, S-96.	0.6	0
84	Identification of the Putative Intestinal Stem Cell Marker DCAMKL-1 in Cirrhosis and Hepatocellular Carcinoma in Human. American Journal of Gastroenterology, 2012, 107, S186-S187.	0.2	0
85	Abstract 4298:microRNA-200cmediates the tumor suppressive effects of Wnt inhibitory factor 1 in human malignant salivary gland cells , 2013, , .		0
86	Abstract 4552: Trimethoxy-cis-stilbene exhibits potent anti-tumor activities via suppression of AKT signaling and cell cycle arrest in virus-induced hepatocellular carcinoma. , 2014, , .		0
87	Abstract 3171: Overexpression of a cancer stem cell marker doublecortin-like kinase (DCLK1) leads to activation of inflammatory cascade during development of virus-induced hepatocellular carcinoma. , 2014, , .		0
88	Abstract LB-48: DCLK1 targeted monoclonal antibodies demonstrate therapeutic potential against pancreatic ductal adenocarcinoma. , 2014, , .		0
89	Abstract 4374: DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma. , 2015, , .		0
90	Abstract 2239: The tumor stem cell marker doublecortin-like kinase (DCLK1) activates inflammatory and carcinogenic signals in hepatocellular carcinoma. , 2015, , .		0

#	Article	IF	CITATIONS
91	Abstract 3361: Targeting tumor/cancer stem cell marker DCLK1 for the treatment of hepatocellular carcinoma and erlotinib-resistant lung adenocarcinoma using Z-3,5,4'-Trimethoxystilbene (Z-TMS). , 2016, , .		0
92	Abstract 3888: DCLK1 is part of an EMT feedback loop and promotes colorectal cancer cell invasion and drug resistance. , 2017, , .		0
93	Abstract 4147: DCLK1 a novel therapeutic target in non-small cell lung cancer. , 2017, , .		0
94	Serum DCLK1 as a Biomarker for Adenoma and Colorectal Neoplasia Detection in Patients Referred for Colonoscopy. American Journal of Gastroenterology, 2017, 112, S123.	0.2	0
95	Abstract 3611: Serum DCLK1 levels are elevated in melanoma patients and it is a novel predictive marker for survival and response. , 2018, , .		0
96	DCLK1 Regulates Pluripotency and Angiogenic Factors via microRNA-Dependent Mechanisms in Pancreatic Cancer. , 2019, , 1-32.		0
97	Abstract 1154: DCLK1 monoclonal antibody-based CAR-T cells as novel treatment strategy against multiple myeloma. , 2019, , .		0